An Effectiveness and Safety Study of Two Doses of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee
Completed
Johnson & Johnson Consumer and Personal Products Worldwide
Phase 3
2002-04-01
The purpose of this study is to determine the safety and effectiveness of 650 mg and 1300 mg
acetaminophen extended release given three times a day for the relief of signs and symptoms
of osteoarthritis of the hip or knee for a period of 12 weeks.
An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee.
Completed
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
1969-12-31
The purpose of this study is to evaluate acetaminophen extended release (3900 mg/day)
compared to placebo for safety and effectiveness in the relief of signs and symptoms of
osteoarthritis of the hip or knee over 12 weeks
An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee.
Completed
Johnson & Johnson Consumer and Personal Products Worldwide
Phase 3
1969-12-31
The purpose of this study is to evaluate acetaminophen extended release (3900 mg/day)
compared to placebo for safety and effectiveness in the relief of signs and symptoms of
osteoarthritis of the hip or knee over 12 weeks
The primary objective of the proposed pilot study is to determine the efficacy of oxymorphone
hydrochloride and propoxyphene/acetaminophen combination in prolonging the time to onset of
pain and reducing the severity of pain associated with walking in patients lumbar spinal
stenosis that have clinical symptoms of neurogenic claudication. Neurogenic claudication is
defined as movement induced leg pain, numbness, heaviness, or vague discomfort in part or all
of one or both legs provoked with walking and standing and relieved by sitting, squatting, or
forward flexion posturing. The secondary objective is to examine the functional benefit of
oxymorphone hydrochloride and propoxyphene/acetaminophen combination with respect to
improvement in duration and distance of walking.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
